Notably, in an automated Trypan Blue exclusion assay for cell viability, FGD3 overexpression strongly increased the breast cancer cells sensitivity to ErSO, while FGD3 knockout rendered the cells resistant to ErSO-induced rapid cell death (Fig. 1G and Fig. S2F). Here, FGD3 is linked to breast carcinoma.